Evidence map›Paper›PMID 39877400›Full record

ArticleOpen forum infectious diseases2025

Hepatitis C Virus Seroprevalence, Incidence, and Screening Patterns in Ontario Preexposure Prophylaxis Users.

Matthew W McGarrity, Ryan Lisk, Paul MacPherson, David Knox, Kevin S Woodward, Jeff Reinhart, John MacLeod, Isaac I Bogoch, Deanna Clatworthy, Mia J Biondi and 4 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Matthew W McGarrityDivision of Infectious Diseases, St Michael's Hospital, Toronto, Canada.ORCID https://orcid.org/0000-0002-6663-0457
Ryan LiskAIDS Committee of Toronto, Toronto, Canada.
Paul MacPhersonDivision of Infectious Diseases, The Ottawa Hospital, Ottawa, Canada.
David KnoxMaple Leaf Medical Clinic, Toronto, Canada.
Kevin S WoodwardHamilton PrEP Clinic, Hamilton, Canada.
Jeff ReinhartSherbourne Health, Toronto, Canada.
John MacLeod790 Bay Street Clinic, Toronto, Canada.
Isaac I BogochToronto General Hospital, University Health Network, Toronto, Canada.
Deanna ClatworthyARCH Clinic, Guelph, Canada.
Mia J BiondiSchool of Nursing, York University, Toronto, Canada.
Sean T SullivanReseau Access Network, Sudbury, Canada.
Alan T W LiCommunity Alliance for Accessible Treatment, Toronto, Canada.
Ann N BurchellMAP Centre for Urban Health Solutions, St Michael's Hospital, Unity Health Toronto, Toronto, Canada.
Darrell H S TanDivision of Infectious Diseases, St Michael's Hospital, Toronto, Canada.ORCID https://orcid.org/0000-0002-3069-2875

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatitis C virus (HCV) has emerged as a sexually transmitted infection in gay, bisexual, and other men who have sex with men (GBM). We estimated the seroprevalence and incidence of HCV infection and examined patterns of HCV testing among GBM using human immunodeficiency virus preexposure prophylaxis (PrEP) in Ontario, Canada. Methods: We analyzed data from the Ontario PrEP Cohort Study (ON-PrEP), a prospective cohort of PrEP users from 10 Ontario clinics. Participants completed an online questionnaire and study staff collected clinical information into a study database biannually for 2 years. We estimated the baseline seroprevalence and incidence of HCV infection and examined patterns of HCV testing during follow-up. We further explored differences in sociodemographic/clinical variables between those with and without prevalent/incident HCV infection through bivariate analysis. Results: Among 557 eligible PrEP users, 382 (68.6%) underwent baseline HCV antibody testing, of whom 5 tested HCV seropositive, giving a seroprevalence of 1.3% (95% confidence interval [CI], .43%-3.03%). Only 245 (43.9%) participants underwent HCV antibody testing after baseline, and median time to participants' first follow-up test was 245 days. During follow-up, 2 participants tested newly HCV seropositive, giving an incidence of 0.47/100 person-years (95% CI, .06-1.69) over 428.9 years of follow-up. Participants with prevalent/incident HCV infection during the study appeared more likely to report giving money, drugs, gifts, or services for sex in the 3 months preceding enrollment compared to those who never tested HCV seropositive ( Conclusions: HCV seroprevalence and incidence were low but not negligible among Ontario PrEP users. HCV antibody and RNA testing were suboptimal.

Indexed as

cohort analysishepatitis C virusincidencepreexposure prophylaxisseroprevalence

Identifiers

PMID39877400
PMCPMC11773187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.